Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT05814432

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

Led by Federal University of Health Science of Porto Alegre · Updated on 2025-02-04

279

Participants Needed

5

Research Sites

97 weeks

Total Duration

On this page

Sponsors

F

Federal University of Health Science of Porto Alegre

Lead Sponsor

G

Gilead Sciences

Collaborating Sponsor

AI-Summary

What this Trial Is About

Phase III trial evaluating the safety and efficacy of a single high dose (10 mg/kg) of liposomal amphotericin B for disseminated histoplasmosis in AIDS patients, in comparison to standard therapy (3 mg/kg of liposomal amphotericin B for two weeks) (INDUCTION trial).

CONDITIONS

Official Title

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients admitted to the participating centers
  • Diagnosed with HIV infection, regardless of antiretroviral therapy use
  • Confirmed disseminated histoplasmosis by microscopy, culture, histopathology, or urinary Histoplasma antigen
  • Patients with central nervous system infection may be included if an alternative diagnosis suggests another CNS infection
  • Patients using fluconazole for oroesophageal candidiasis may be included
Not Eligible

You will not qualify if you...

  • Refusal to participate in the trial
  • Previous diagnosis of histoplasmosis
  • Pregnant or lactating women
  • Renal failure at any time (serum creatinine > 2x upper limit of normal)
  • Previous severe reaction to a polyene antifungal
  • Received more than one dose of a polyene antifungal in the last 48 hours
  • Suspected central nervous system involvement of histoplasmosis
  • Prospect of death within 48 hours after selection
  • Concomitant diagnosis of cryptococcus or leishmaniasis under treatment or prophylaxis with amphotericin
  • Inability to take oral medication as judged by the principal investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Hospital de Doenças Tropicais

Goiânia, Goiás, Brazil

Actively Recruiting

2

Hospital Giselda Trigueiro

Natal, Rio Grande do Norte, Brazil

Actively Recruiting

3

Federal University of Health Sciences of Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil, 90050-170

Actively Recruiting

4

Hospital de Clinicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Actively Recruiting

5

Hospital Geral de Roraima

Boa Vista, Roraima, Brazil

Actively Recruiting

Loading map...

Research Team

A

Alessandro C Pasqualotto, MD PhD

CONTACT

D

Diego R Falci, MD PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here